Zhaoke Ophthalmology Signs Strategic MOU With Brazil’s Teuto at BIO 2026 – First Latin America Eye‑Care Market Entry

Zhaoke Ophthalmology Limited (HKG: 6622) announced that it signed a strategic cooperation memorandum with Brazilian pharmaceutical company Laboratório Teuto Brasileiro S.A. during the BIO International Convention 2026. The two parties will jointly explore potential opportunities in the ophthalmic field across the Latin American market.

Deal Overview

Strategic Rationale

• First Brazil Footprint: The MOU marks Zhaoke Ophthalmology’s first strategic cooperation memorandum in the Brazilian market, establishing an entry point into Latin America’s largest pharmaceutical market.
• Portfolio + Distribution: The collaboration aims to integrate Zhaoke Ophthalmology’s extensive portfolio of innovative ophthalmic products with Teuto’s commercialization network covering Brazil.
• Market Access: Teuto’s established domestic distribution channels provide a potential route to introduce advanced ophthalmic treatment solutions to local patients.

Market Impact & Outlook

• Latin American Opportunity: Brazil is the region’s largest pharmaceutical market, with growing demand for specialty eye‑care therapies — a segment currently underserved locally.
• Commercialization Pathway: The MOU sets a framework for the two parties to evaluate product selection, registration, and distribution, pending further definitive agreements.
• Global Expansion Signal: The partnership extends Zhaoke Ophthalmology’s strategy of taking its ophthalmic innovation portfolio beyond Asia through local commercial partners.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the parties’ collaboration plans and market expansion expectations. Actual results may differ due to risks including regulatory approvals, definitive agreement terms, and market conditions.-Fineline Info & Tech